Epstein Secrets

d gears in mid-2012 to move away from biomass and to focus on making syngas from natural gas. This is not a new idea: Exx- onMobil built a plant in New Zealand in 1986 to turn natural gas into methanol and then gasoline, but aban- doned its efforts when the price of petroleum dropped dramatically in the mi

her crops. Solazyme is making oils and specialty fats to sell at high margins to cosmetics and food companies, as is would-be microbial fuel-maker Amyris. The industry for "advanced biofuels is literally in its infancy," con- cedes Jonathan Wolfson, Solazyme CEO. The allure of Primus's technology is

ous AEs were reported. A randomized, double- blind, placebo-controlled trial to extend these findings to a larger population is ongoing in Australia, New Zealand, and the U.S. Figure 130 ZYNOO2 Produced Reductions In ADAMS At 12 Weeks... Figure 131 ...And Efficacy Persisted Out To 12 Months In An Extension St

e highlight two such agreements from the past few months below. Amyris / Undisclosed Partner (February 2019; Valued Up to $255MM) In February 2019, Amyris announced that it has signed an agreement for cannabinoid development, licensing, and commercialization in a partnership valued at up to $255MM (not

other crops. Solazyme is making oils and specialty fats to sell at high margins to cosmetics and food companies, as is would-be microbial fuel-maker Amyris. The industry for “advanced biofuels is literally mm its infancy,” con- cedes Jonathan Wolfson, Solazyme CEO. The allure of Primus’s technology 1s i

ged gears in mid-2012 to move away from biomass and to focus on making syngas from natural gas. This is not a new idea: Exx- onMobil built a plant in New Zealand in 1986 to turn natural gas into methanol and then gasoline, but aban- doned its efforts when the price of petroleum dropped dramatically in the mid